DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+13.89%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$372M
AUM Growth
+$372M
(+1.3%)
Cap. Flow
-$24.6M
Cap. Flow
% of AUM
-6.63%
Top 10 Holdings %
Top 10 Hldgs %
47.82%
Holding
98
New
8
Increased
10
Reduced
34
Closed
10
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$3.55M |
| 2 |
MediWound
MDWD
|
$1.99M |
| 3 |
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
|
$1.71M |
| 4 |
Larimar Therapeutics
LRMR
|
$1.68M |
| 5 |
Kura Oncology
KURA
|
$1.21M |
Top Sells
Sector Composition
| 1 | Healthcare | 81.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $44.9M | 12.07% | 566,000 -47,000 | -8% | -$3.73M |
|
2
Stereotaxis
STXS
$261M
| $24.6M | 6.62% | 13,680,554 | – | – |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $17.2M | 4.63% | 261,235 -45 | -0% | -$2.97K |
|
|
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $16.6M | 4.48% | 110,100 | – | – |
|
5
Ascendis Pharma
ASND
$11.8B
| $14M | 3.77% | 135,712 -3,500 | -3% | -$361K |
|
6
Xenon Pharmaceuticals
XENE
$2.98B
| $13.5M | 3.64% | 375,223 -63,400 | -14% | -$2.29M |
|
7
Adicet Bio
ACET
$59.9M
| $13.3M | 3.58% | 935,766 | – | – |
|
8
Fate Therapeutics
FATE
$120M
| $12.1M | 3.25% | 539,940 -11,000 | -2% | -$247K |
|
9
iShares Biotechnology ETF
IBB
$5.6B
| $12M | 3.22% | 102,500 | – | – |
|
|
10
Revolution Medicines
RVMD
$7.1B
| $9.46M | 2.54% | 479,785 +180,000 | +60% | +$3.55M |
|
11
Cytokinetics
CYTK
$4.23B
| $8.92M | 2.4% | 183,995 -27,500 | -13% | -$1.33M |
|
12
Syndax Pharmaceuticals
SNDX
$1.41B
| $8.54M | 2.3% | 355,487 -15,500 | -4% | -$372K |
|
13
Neurocrine Biosciences
NBIX
$13.8B
| $8.51M | 2.29% | 80,155 -2,500 | -3% | -$266K |
|
14
IDEAYA Biosciences
IDYA
$2.15B
| $8.04M | 2.16% | 538,561 -10,000 | -2% | -$149K |
|
15
Edgewise Therapeutics
EWTX
$1.51B
| $7.69M | 2.07% | 781,112 +85,153 | +12% | +$838K |
|
16
Nurix Therapeutics
NRIX
$714M
| $7.38M | 1.99% | 566,695 | – | – |
|
|
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $7.2M | 1.94% | 401,476 -1,000 | -0.2% | -$17.9K |
|
|
SAGE
18
DELISTED
Sage Therapeutics
SAGE
| $7.06M | 1.9% | 180,306 | – | – |
|
|
KRTX
19
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $6.5M | 1.75% | 28,886 -33,167 | -53% | -$7.46M |
|
|
CBAY
20
DELISTED
Cymabay Therapeutics
CBAY
| $5.96M | 1.6% | 1,703,235 -84,334 | -5% | -$295K |
|
21
DexCom
DXCM
$29.5B
| $5.84M | 1.57% | 72,552 | – | – |
|
22
Merus
MRUS
$4.98B
| $5.55M | 1.49% | 276,893 +14,002 | +5% | +$280K |
|
|
MORF
23
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $5.53M | 1.49% | 195,467 | – | – |
|
24
Alector
ALEC
$238M
| $5.04M | 1.35% | 532,438 -20,000 | -4% | -$189K |
|
|
MRTX
25
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5M | 1.35% | 71,600 -8,000 | -10% | -$559K |
|